The Latest Breaking News from Brain

The time fathers devote to child care every week has tripled over the past 50 years in the United States. The increase in fathers’ involvement in child rearing is even steeper in countries that have expanded paid paternity leave or created incentives for fathers to take leave, such as Germany,…

Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients

Anna Binks was in agony after being diagnosed with a brain tumour, leaving her children terrified

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

From seizures to sudden weakness or speech disturbances, these are some of the red flags that could indicate the onset of the condition

Patients unlikely to receive lecanemab before 2026 and health service does not yet have necessary infrastructure

Neuroscientists and psychologists are researching new treatments that might help us finally understand why nightmares take over our minds and how to quell them.

The FDA will soon decide whether to approve Eisai's experimental drug lecanemab.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Recent lecanemab trials are reason for hope, although health services may struggle to deliver treatments, says dementia researcher Jonathan Schott

Lecanemab was found to have reduced memory decline by targeting and clearing amyloid, which is one of the proteins that build up in the brains of people with the disease